Easily Available Blood Test Neutrophil-To-Lymphocyte Ratio Predicts Progression in High-Risk Non-Muscle Invasive Bladder Cancer

Martha, Orsolya; Porav-Hodade, Daniel; Bălan, Daniel; Tătaru, Octavian Sabin; Sin, Anca; Chibelean, C.; Vartolomei, Mihai Dorin

doi:10.1515/rrlm-2017-0016

Cited by 8 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnostic performance of hematologic ratios for CD Sarikaya et al 2014Sarikaya et al , 2015 Our results (25,26), have also been studied in CD (27,28); they had good diagnostic performance in our cohort also, but RDW/LY ratio proved to be better (Table 3). To the best of our knowledge, this is the first study to investigate the diagnostic accuracy of RDW/LY ratio to diagnose CD.…”

Section: Discussionsupporting

confidence: 56%

Diagnostic accuracy of red blood cell distribution width-to-lymphocyte ratio for celiac disease

Balaban

Popp

Acs

et al. 2018

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 56%

Diagnostic accuracy of red blood cell distribution width-to-lymphocyte ratio for celiac disease

Balaban

Popp

Acs

et al. 2018

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…Thinking about the future predictive models, to better understand urothelial neoplasm behavior and to better understand recurrence and progression multiple biomarkers have been studied as predictors for NMIBC patients outcomes, [ 26 ] the closest to be embraced in clinical practice is neutrophil-to-lymphocyte ratio, which is accessible and a less costly biomarker. [ 27 ] Elevated neutrophil-to-lymphocyte ratio was demonstrated to be an independent predictor for poor OS, cancer-specific survival, recurrence, and progression in BC patients. [ 28 ]…”

Section: Discussionmentioning

confidence: 99%

Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors

et al. 2018

Self Cite

View full text Add to dashboard Cite

To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs). Secondary aim was to investigate clinical and pathologic prognostic factors for OS of Ta patients, except G3/high grade (HG).A total of 243 patients, retrospectively selected, with Ta nonmuscle invasive bladder cancer (NMIBC) underwent TURBT between January 2006 and December 2008 (median follow-up 109 months). Inclusion criteria were: Ta at first manifestation, G1 or G2 grade with no associated carcinoma in situ (CIS). Seventy-nine patients were excluded due to concomitant CIS (1), G3/HG tumors (47), and lost to follow-up (31). Ethical approval was obtained from the Ethical Committee of the Mures County Hospital. Statistical analysis was performed using STATA 11.0.Following inclusion criteria, 164 patients with primary G1 or G2 Ta tumors, were enrolled. Recurrence was observed in 26 (15.8%) and progression in 5 (3%) patients. Ten-year survival in G1 patients was 67.8% (CI 54.3–78.1) and in G2 patients 59% (CI 49–67.3) (P = .31). Univariable and multivariable logistic regression analysis underlined that advanced age at diagnosis (hazard ratio [HR] 1.10) and no Bacillus Calmette–Guerin (BCG) treatment (HR 0.24 and 0.29) were independent predictors for death at 10 years after diagnosis.Long-term analysis confirms that patients with well differentiated (G1) and moderately well differentiated (G2) Ta tumors have similar OS. A longer OS was even reported in those who underwent BCG adjuvant therapy.

show abstract

“…Limitations of this study include its retrospective nature; however, we followed patients for almost 10 years after TURBT. Additionally, sample size was another limitation, but if we consider the long follow-up and previous results we reported (35) for high-grade NMIBC (those that also came from a mono-center cohort and that were further validated in a multi-institutional cohort (23)), we can consider our results reliable. Of course, these findings must be externally validated in a multi-institutional study.…”

Section: Fig 3 Overall Survival Estimates Of 54 Patients With Pta Bmentioning

confidence: 92%

The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer

Martha

Bălan

Porav-Hodade

et al. 2020

Revista Romana De Medicina De Laborator

Self Cite

View full text Add to dashboard Cite

Introduction:The peritumoral inflammatory reaction has a substantial importance in the oncologic outcome of bladder cancer (BC). One biomarker proven to be practical and accessible is the NLR (neutrophil-to-lymphocyte ratio) for high risk non-muscle invasive bladder cancer (NMIBC). The aim of the study was to investigate the role of NLR as a prognostic biomarker for disease recurrence, progression and survival of p Ta (pathological assesment of the primary tumor) NMIBC. Material and Methods: In our retrospective study we included 54 patients with pTa NMIBC from a total of 235 patients who underwent transurethral resection of bladder tumor (TURBT) during two consecutive years: January 2007 -December 2008]. Criteria for inclusion were: primary tumor, low-grade, with NLR available at 2 weeks prior to TURBT. NLR was considered altered if higher than 3. Results: The median age of the patients included was 63 years ). Most of the patients had NLR<3 (37 patients). Median EORTC (European Organization of Research and Treatment of Cancer) Recurrence Score was 4 (IQR 1-6), while EORTC Progression Score was 3 (IQR 0-6), respectively. Recurrence occurred in 8 out of 54 (14.81 %) patients and progression was identified in 2 out of 54 (3.70 %) patients with muscle-invasive BC during follow-up. NLR>3 was not associated with clinical and pathological factors. In multivariable Cox regression analyses NLR as a continuous variable was an independent predictive factor for recurrence. Recurrence-free survival (RFS) Kaplan-Meier analysis did not show a statistical significance between NLR groups: 82.67% vs. 64.12%, p=0.26. Kaplan-Meier analysis showed a lower Progression-free survival (PFS) in the NLR>3 group: 94.12% vs. 100%, p=0.04. During follow-up (106 months) 18 patients deceased with

show abstract

Easily Available Blood Test Neutrophil-To-Lymphocyte Ratio Predicts Progression in High-Risk Non-Muscle Invasive Bladder Cancer

Abstract: Introduction: The inflammatory response surrounding the tumour has a major importance in the oncologic outcome of bladder cancers. One marker proved to be useful and accessible is NLR (neutrophil-to-lymphocyte ratio in patients that did not present any progression during the

Cited by 8 publications

References 22 publications

Diagnostic accuracy of red blood cell distribution width-to-lymphocyte ratio for celiac disease

Diagnostic accuracy of red blood cell distribution width-to-lymphocyte ratio for celiac disease

Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors

The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer

Contact Info

Product

Resources

About